Literature DB >> 20217045

Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation.

Christophe Faisy1, Amel Mokline, Olivier Sanchez, Jean-Marc Tadié, Jean-Yves Fagon.   

Abstract

PURPOSE: To evaluate the effects of a single daily dose of acetazolamide (ACET) on metabolic alkalosis and respiratory parameters in weaning chronic obstructive pulmonary disease (COPD) patients from invasive mechanical ventilation.
DESIGN: Case-control study.
SETTING: An 18-bed intensive care unit (ICU) in a university hospital. PATIENTS: Twenty-six intubated COPD patients with mixed metabolic alkalosis (serum bicarbonate >26 mmol/l and arterial pH >or=7.38) were compared with a historical control group (n = 26) matched for serum bicarbonate, arterial pH, age, and severity of illness at admission to ICU. ACET administration (500 mg intravenously) was monitored daily according to arterial blood gas analysis from readiness to wean until extubation.
RESULTS: ACET was administered 4 (1-11) days throughout the weaning period. Patients with ACET treatment significantly decreased their serum bicarbonate (p = 0.01 versus baseline) and arterial blood pH (p < 0.0001), increased their PaO(2)/FiO(2) ratio (p = 0.04), but did not change their PaCO(2) (p = 0.71). Compared with matched controls, administration of ACET did not improve arterial blood gas and respiratory parameters except PaO(2)/FiO(2) ratio (p = 0.03). ACET patients and their matched controls had similar duration of weaning. Extubation success rate was not significantly different between groups, and causes of reintubation were comparable.
CONCLUSIONS: ACET used at the dosage of 500 mg per day reduces metabolic alkalosis but has no benefit in terms of improving PaCO(2) or respiratory parameters in weaning COPD patients from mechanical ventilation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20217045     DOI: 10.1007/s00134-010-1795-7

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  13 in total

Review 1.  Metabolic alkalosis.

Authors:  A Khanna; N A Kurtzman
Journal:  Respir Care       Date:  2001-04       Impact factor: 2.258

2.  P 0.1/PIMax: an index for assessing respiratory capacity in acute respiratory failure.

Authors:  R Fernández; J Cabrera; N Calaf; S Benito
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 3.  Airway occlusion pressure.

Authors:  W A Whitelaw; J P Derenne
Journal:  J Appl Physiol (1985)       Date:  1993-04

4.  Acetazolamide in the treatment of ventilatory failure complicating acute metabolic alkalosis.

Authors:  G E Dickinson; M L Myers; M Goldbach; W Sibbald
Journal:  Anesth Analg       Date:  1981-08       Impact factor: 5.108

5.  Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial.

Authors:  J E Mazur; J W Devlin; M J Peters; M A Jankowski; M C Iannuzzi; B J Zarowitz
Journal:  Crit Care Med       Date:  1999-07       Impact factor: 7.598

6.  Acetazolamide and breathing. Does a clinical dose alter peripheral and central CO(2) sensitivity?

Authors:  L J Teppema; A Dahan
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

Review 7.  Metabolic alkalosis in the critically ill.

Authors:  N R Webster; V Kulkarni
Journal:  Crit Rev Clin Lab Sci       Date:  1999-10       Impact factor: 6.250

8.  Effects of acetazolamide and furosemide on ventilation and cerebral blood volume in normocapnic and hypercapnic patients with COPD.

Authors:  Marjo J T van de Ven; Willy N J M Colier; Marco C van der Sluijs; Berend Oeseburg; Piet Vis; Hans Folgering
Journal:  Chest       Date:  2002-02       Impact factor: 9.410

9.  Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis.

Authors:  P Berthelsen
Journal:  Intensive Care Med       Date:  1982       Impact factor: 17.440

10.  Oxygen uptake and carbon dioxide elimination after acetazolamide in the critically ill.

Authors:  P Berthelsen; I Gøthgen; B Husum; E Jacobsen
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

View more
  9 in total

1.  Effects of early administration of acetazolamide on the duration of mechanical ventilation in patients with chronic obstructive pulmonary disease: still far from the truth?

Authors:  Mabrouk Bahloul; Rania Ammar; Abir Bouattour; Samar Bellil; Hedi Chelly; Anis Chaari; Mounir Bouaziz
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

2.  Acetazolamide use in severe COPD exacerbations requiring invasive mechanical ventilation: impact on duration of mechanical ventilation.

Authors:  Mabrouk Bahloul; Kamilia Chtara; Hedi Chelly; Kais Regaieg; Anis Chaari; Mounir Bouaziz
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

Review 3.  Acetazolamide: a second wind for a respiratory stimulant in the intensive care unit?

Authors:  Nicholas Heming; Saïk Urien; Christophe Faisy
Journal:  Crit Care       Date:  2012-08-07       Impact factor: 9.097

4.  Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients.

Authors:  Nicholas Heming; Christophe Faisy; Saïk Urien
Journal:  Crit Care       Date:  2011-09-14       Impact factor: 9.097

5.  What is new in critical illness and injury science? Acetazolamide in decompensated respiratory failure!

Authors:  Jacopo Colombo
Journal:  Int J Crit Illn Inj Sci       Date:  2015 Jan-Mar

6.  Impact of acetazolamide use in severe exacerbation of chronic obstructive pulmonary disease requiring invasive mechanical ventilation.

Authors:  Mabrouk Bahloul; Anis Chaari; Ahmed Tounsi; Olfa Turki; Kamilia Chtara; Chokri Ben Hamida; Hatem Ghadhoune; Hassen Dammak; Hedi Chelly; Mounir Bouaziz
Journal:  Int J Crit Illn Inj Sci       Date:  2015 Jan-Mar

7.  A letter in response to impact of acetazolamide use in severe exacerbation of chronic obstructive pulmonary disease requiring invasive mechanical ventilation.

Authors:  Animesh Ray
Journal:  Int J Crit Illn Inj Sci       Date:  2015 Jul-Sep

8.  Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patients.

Authors:  Nicholas Heming; Saïk Urien; Virginie Fulda; Ferhat Meziani; Arnaud Gacouin; Marc Clavel; Benjamin Planquette; Christophe Faisy
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

9.  Carbonic anhydrase inhibitors in patients with respiratory failure and metabolic alkalosis: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Bassem Y Tanios; Maryam O Omran; Carlos Noujeim; Tamara Lotfi; Samir S Mallat; Pierre K Bou-Khalil; Elie A Akl; Houssam S Itani
Journal:  Crit Care       Date:  2018-10-29       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.